根据发布于美国血液学协会杂志《Bloo》上的消息:Cell Therapeutics公司的 Trisenox（三氧化二砷）和维生素C联合用药方案可有效治疗顽固性多发性骨髓瘤。Miami大学医学院的研究发现:该两药可绕开肿瘤的抗药机制——该抗药性包括使化疗药物泵出癌细胞、改变细胞死亡的基因表达、多发性骨髓瘤细胞的解毒作用。 According to the publication in Bloo, the American Association of Hematology: Cell Therapeutics’ combination of Trisenox and Vitamin C is effective in the treatment of refractory multiple myeloma. A study by the Miami University School of Medicine found that the two drugs bypass the tumor’s drug resistance mechanisms, which include pumping chemotherapeutic drugs out of cancer cells, altering gene expression of cell death, and detoxification of multiple myeloma cells.